Olivier Danos is the Senior Vice President and Chief Scientific Officer for REGENXBIO. Prior to joining REGENXBIO, Olivier was Senior Vice President, Cell and Gene Therapy at Biogen Inc.
Olivier was co-founder of Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates. He has also served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals, Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon, and Senior Director of Research at Somatix Therapy Corporation. Olivier has directed gene therapy research at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research, and the Pasteur Institute in Paris.